All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MDS Hub

MDS Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2023-06-07T11:08:43.000Z

EHA2023 abstracts: What’s hot in lymphoma and CLL?

By Abhilasha Verma, Quintina Dawson
Jun 7, 2023
Share:

Bookmark this article

To help navigate the exciting content being presented at the EHA2023 Congress, the Lymphoma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in lymphoma and chronic lymphocytic leukemia.

Indolent and mantle cell NHL

S220

Real-world outcomes of brexucabtagene autoleucel (BREXU-CEL) for relapsed or refractory mantle cell lymphoma: a CIBMTR subgroup analysis by prior treatment

S221

Long-term results of the FIL MCL0208 trial comparing lenalidomide maintenance (LEN) vs observation (OBS) after autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL)

S222

Epcoritamab with rituximab + lenalidomide (R2) provides durable responses in patients with high-risk follicular lymphoma, regardless of POD24 status

S223

Real-world early outcomes of axicabtagene ciloleucel for relapsed or refractory follicular lymphoma

P1080

Zanubrutinib plus obinutuzumab versus obinutuzumab in patients with relapsed/refractory follicular lymphoma: updated analysis of the ROSEWOOD study

P1078

Mosunetuzumab demonstrates durable responses in patients with relapsed and/or refractory follicular lymphoma who have received ≥2 prior therapies: updated analysis of a pivotal phase II study

P1107

ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel versus standard-of-care therapy in patients with relapsed or refractory follicular lymphoma

Hodgkin lymphoma

S217

Post-transplant nivolumab plus unselected autologous lymphocytes in refractory Hodgkin lymphoma results in very high remission rate and excellent survival and it is associated with NK cell expansion

S218

Correlation between progression-free and overall survival in patients with classical Hodgkin lymphoma: a comprehensive analysis of individual patient data from randomized GHSG trials

S219

Predicting thrombotic risk in patients with Hodgkin lymphoma: a multicentric study of ThroLy and Khorana  risk scores

T-cell lymphoma

S225

Allogeneic stem cell transplantation for NK/T-CELL lymphoma in the era of asparaginase-based chemotherapy: a retrospective analysis of the EBMT lymphoma working party

S226

Efficacy of anti-PD1 therapy  in relapsed or refractory extranodal NK/T cell lymphoma: a matched cohort analysis from the LYSA

S237

The genetic subtypes and the tumor microenvironment signatures are associated with distinct outcomes in peripheral T-cell lymphoma

 

Aggressive B-NHL

S227

Initial safety data from the phase 3 POLAR BEAR trial in elderly or frail patients with diffuse large cell lymphoma, comparing R-POLA-MINI-CHP and R-MINI-CHOP

S229

Prophylactic efficacy of intrathecal versus intravenous methotrexate for CNS relapse in high-risk diffuse large B cell lymphoma : a phase III randomized, controlled study

S230

CD22 CAR T cell therapy is safe and effective in patients with large B cell lymphoma who have relapsed after CD19 car t cell therapy.

S233

Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma in transplant-ineligible patients: final analysis of ALYCANTE, a phase 2 LYSA study

S234

Updated clinical results of first-in-human study of CD19/BCMA dual-targeting fast CAR-T GC012F for patients with relapsed/refractory B-cell non-Hodgkin’s lymphoma

P1127

Final analysis of Australasian leukaemia & lymphoma group NHL29: a phase II study of ibrutinib, rituximab and mini-CHOP in very elderly patients with newly diagnosed DLBCL

P1129

Glofitamab monotherapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL): extended follow-up and landmark analyses from a pivotal phase II study

P1154

Efficacy of subcutaneous epcoritamab vs axi-cel in R/R DLBCL CAR T-naive and CAR T-eligible patients: an indirect comparison

Chronic lymphocytic leukemia

S144

BTK and BCL-2 activity at baseline predicts MRD status for chronic lymphocytic leukemia patients treated with ibrutinib + venetoclax in the HOVON 141/VISION trial

S145

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized CLL14 study

S146

Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor (CBTKI) pre-treated chronic lymphocytic leukemia (CLL) patients: results from the phase I/II BRUIN study

S200

Ibrutinib versus placebo in patients with asymptomatic, treatment-naïve early stage chronic lymphocytic leukemia (CLL): final results of the phase 3, double-blind, placebo-controlled CLL12 trial

S201

Final 7-year follow up and retreatment substudy analysis of MURANO: venetoclax-rituximab (VENR)-treated patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)

 

Advances in disease biology

S257

CAR T cells and their immune environment shape distinct immune profiles in response and toxicity in B cell lymphoma patients

EHA 2023 abstracts

To download this document, click below.

Download here

More about...
EHA 2023

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Novel treatments in R/R CLL: Updates from EHA 2023

Here, we summarize two treatment updates in R/R CLL presented at the European Hematology Association (EHA) 2023 Congress.

Aug 8, 2023
Add bookmark

Novel treatments in R/R CLL: Updates from EHA 2023

Here, we summarize two treatment updates in R/R CLL presented at the European Hematology Association (EHA) 2023 Congress.

Aug 8, 2023
Add bookmark

Answering the common challenges facing real-world CAR T-cell therapies

During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session on the ins and outs of CAR T-cells in the real world. Here, Michael Hudecek,...

Jul 21, 2023
Add bookmark

Answering the common challenges facing real-world CAR T-cell therapies

During the EHA 2023 Hybrid Congress, the Lymphoma Hub and Multiple Myeloma Hub held a joint session on the ins and outs of CAR...

Jul 21, 2023

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox